

Longevity & Bioidentical Hormones

Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. *J Clin Endocrinol Metab.* 2009 May;94(5):1732-9.

Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. *Heart.* 2004 Aug;90(8):871-6.

Besson A, Salemi S, Gallati S, et al. Reduced longevity in untreated patients with isolated growth hormone deficiency. *J Clin Endocrinol Metab.* 2003 Aug;88(8):3664-7.

Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. *J Clin Endocrinol Metab.* 2004 Jan;89(1):114-120.

Moffat SD, Zonderman AB, Metter EJ, et al. Free testosterone and risk for Alzheimer disease in older men. *Neurology.* 2004 Jan 27;62(2):188-193.

Khaw KT, Dowsett M, Folkard E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. *Circulation.* 2007 Dec 4;116(23):2694-701.

Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. *J Clin Endocrinol Metab.* 2004 Jul;89(7):3313-3318.

Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). *Diabetes Care.* 2007 Feb;30(2):234-238.

Hak AE, Witteman JC, de Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. *J Clin Endocrinol Metab.* 2002 Aug;87(8):3632-3639.

Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. *Arch Intern Med.* 2007 Nov 12;167(20):2249-54.

Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. *Arch Intern Med.* 2006 Aug 14-28;166(15):1660-1665.

Asvold BO, Bjørø T, Nilsen TI, et al. Thyrotropin levels and risk of fatal coronary heart disease: the HUNT study. *Arch Intern Med.* 2008 Apr 28;168(8):855-60.

Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. *Arch Intern Med.* 2008 Jun 9;168(11):1174-80.

Schumacher M, Guennoun R, Ghomari A, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. *Endocr Rev.* 2007 Jun;28(4):387-439.

Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. *Endocrinology.* 2002 Jan;143(1):205-212.

Enomoto M, Adachi H, Fukami A, et al. Serum dehydroepiandrosterone sulfate levels predict longevity in men: 27-year follow-up study in a community-based cohort (Tanushimaru study). *J Am Geriatr Soc.* 2008 Jun;56(6):994-998.

Fukui M, Kitagawa Y, Nakamura N, et al. Serum dehydroepiandrosterone sulfate concentration and carotid atherosclerosis in men with type 2 diabetes. *Atherosclerosis.* 2005 Aug;181(2):339-344.

New study finds removing ovaries during hysterectomy increases risk of death, outweighs benefits. *Business Wire.* 2009 April 20. Accessed from <http://www.businesswire.com/news/home/20090420005411/en/Study-Finds-Removing-Ovaries-Hysterectomy-Increases-Risk>

Parker WH, Broder MS, Chang E, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. *Obstet Gynecol.* 2009 May;113(5):1027-37.

Shoupe D, Parker WH, Broder MS, et al. Elective oophorectomy for benign gynecological disorders. *Menopause.* 2007 May-Jun;14(3 Pt 2):580-585.

Mäkinen J, Jarvisalo MJ, Pöllänen P, et al. Increased carotid atherosclerosis in andropausal middle-aged men. *J Am Coll Cardiol.* 2005 May 17;45(10):1603-8.

Rivera CM, Grossardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. *Menopause.* 2009 Jan-Feb;16(1):15-23.

Parker WH, Manson JE. Oophorectomy and cardiovascular mortality: Is there a link? *Menopause.* 2009 Jan-Feb;16(1):1-2.

Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. *J Clin Endocrinol Metab.* 2008 Jan;93(1):68-75.

Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. *Eur J Endocrinol.* 2006 Jun;154(6):899-906.

Rice D, Brannigan RE, Campbell RK, et al. Men's health, low testosterone, and diabetes: individualized treatment and a multidisciplinary approach. *Diabetes Educ.* 2008 Nov-Dec;34 Suppl 5:97S-112S.

Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. *J Natl Cancer Inst.* 1995 Apr 5;87(7):517-23.

Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. *JAMA.* 2002 Nov 6;288(17):2123-2129.

Harden CL. The mysterious effect of reproductive hormones on cognitive function: scientific knowledge in search of an application. *J Gend Specif Med.* 2000 Oct;3(7):33-37.

Loret De Mola JR. Effects of estrogen use on the risk of alzheimer's disease. *Biomedicina.* 2000 Jan;3(1):6-7.

Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. *Clin Obstet Gynecol.* 2008 Sep;51(3):564-580.

Saunders-Pullman RJ. Another potential benefit from HRT: Slowing Parkinson's. *Geriatrics.* 1998 Jun;53(6):91.

Malkin CJ, Pugh PJ, West JN, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. *Eur Heart J.* 2006 Jan;27(1):57-64.

Salpeter SR, Cheng J, Thabane L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. *Am J Med.* 2009 Nov;122(11):1016-1022.

Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. *Arch Intern Med.* 2008 Jun 23;168(12):1340-9.

Review of WHI & HERS trials

Klaiber EL, Vogel W, Rako S. A critique of the Women's Health Initiative hormone therapy study. *Fertil Steril.* 2005 Dec;84(6):1589-1601.

Gambrell RD. The women's health initiative reports: Critical review of the findings. *The Female Patient.* 2004;29:25-41.

Mishell DR, McNeille LG. Hormone Therapy and Coronary Heart Disease: Evolving evidence from clinical trials. *J of Family Practice.* 2007 Nov;15(2):S1-S6.

Salpeter SR, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. *J Gen Intern Med.* 2004 Jul;19(7):791-804.

Wood MJ, Cox JL. HRT to prevent cardiovascular disease. What studies show, how to advise patients. *Postgrad Med.* 2000 Sep 1;108(3):59-60, 63-6, 69-72.

Brzyski RG. Hormone replacement therapy and cardiovascular disease. *Biomedicina.* 2000 Jan;3(1):126-128.

Dubey RK, Jackson EK, Gillespie DG, et al. Medroxyprogesterone abrogates the inhibitory effects of estradiol on vascular smooth muscle cells by preventing estradiol metabolism. *Hypertension.* 2008 Apr;51(4):1197-202.

Booth EA, Lucchesi BR. Medroxyprogesterone acetate prevents the cardioprotective and anti-inflammatory effects of 17beta-estradiol in an in vivo model of myocardial ischemia and reperfusion. *Am J Physiol Heart Circ Physiol.* 2007 Sep;293(3):H1408- 15.

Review of Different BHRT

Cirigliano M. Bioidentical hormone therapy: a review of the evidence. *J Womens Health.* 2007 Jun;16(5):600-631.

Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. *Acta Endocrinol Suppl.* 1980;233:17-27.

Lauritzen C. Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints. *Horm Metab Res.* 1987 Nov;19(11):579-584.

Head KA. Estriol: safety and efficacy. *Altern Med Rev.* 1998 Apr;3(2):101-113.

Takahashi K, Okada M, Ozaki T, et al. Safety and efficacy of oestriol for symptoms of

natural or surgically induced menopause. *Hum Reprod.* 2000 May;15(5):1028-1036.

Teoh H, Quan A, Leung SW, Man RY. Vascular effects of estrone and diethylstilbestrol in porcine coronary arteries. *Menopause.* 2009 Jan-Feb;16(1):104-109.

Karim R, Mack WJ, Lobo RA, et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. *Menopause.* 2005 Jul-Aug;12(4):366-73.

Pratt JH, Longcope C. Estriol production rates and breast cancer. *J Clin Endocrinol Metab.* 1978 Jan;46(1):44-7.

Lippman M, Monaco ME, Bolan G. Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. *Cancer Res.* 1977 Jun;37(6):1901-1907.

Siiteri PK, Sholtz RI, Cirillo PM, et al. Prospective study of estrogens during pregnancy and risk of breast cancer. *Public Health Institute.* 2002.

Vooijs GP, Geurts TB. Review of the endometrial safety during intravaginal treatment with estriol. *Eur J Obstet Gynecol Reprod Biol.* 1995 Sep;62(1):101-106.

Nachtigall LE. Bioidentical versus nonbioidentical hormones. Proceedings from the postgraduate course presented prior to the 17th annual meeting of the North American Menopause Society. 2006 October 11;15-19.

Hormones & Cancer

Fuhrman B, Barba M, Schünemann HJ, et al. Basal growth hormone concentrations in blood and the risk for prostate cancer: a case-control study. *Prostate.* 2005 Jul 1;64(2):109-15.

Devi GR, Sprenger CC, Plymate SR, Rosenfeld RG. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. *Prostate.* 2002 May 1;51(2):141-52.

Melmed S. Acromegaly and cancer: not a problem? *J Clin Endocrinol Metab.* 2001 Jul;86(7):2929-34.

Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. *Prostate.* 1995 Jul;27(1):25-31.

Chen C, Lewis SK, Voigt L, et al. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. *Cancer.* 2005 Jan 1;103(1):76-84.

Rhoden EL, Morgentaler A. Medical Progress: Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring. *N Engl J Med.* 2004 Jan; 350:482- 492.

Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. *Urology.* 2006 Dec;68(6):1263-7.

Scherr DS, Pitts WR Jr. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. *J Urol.* 2003 Nov;170(5):1703-8.

Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. *Br J Cancer*. 1999 Jun;80(7):930-4.

Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. *Int J Impot Res*. 2009 Jan-Feb;21(1):9-23.

Savage L, Widener A. Sex Hormones Unrelated to Prostate Cancer Risk. *JNCI*. 2008;100(3):157.

Page JH, Colditz GA, Rifai N, et al. Plasma adrenal androgens and risk of breast cancer in premenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2004 Jun;13(6):1032-6.

Heikkilä R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. *Cancer*. 1999 Jul 15;86(2):312-5.

Jancin B. HRT Safe for Survivors of Early-Stage Breast Ca. *Family Practice News*. 2001 Jun 1.

Goldman EL. ERT shows no risk in breast cancer survivors. (unable to find full reference)

Johnson K. ERT Does Not Increase Breast Cancer Recurrence or Mortality. *Family Practice News*. 1999 May 15.

Campagnoli C, Clavel-Chapelon F, Kaaks R, et al. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. *J Steroid Biochem Mol Biol*. 2005 Jul;96(2):95-108.

Lea R, Bannister E, Case A, Levesque P, et al. Use of hormonal replacement therapy after treatment of breast cancer. *J Obstet Gynaecol Can*. 2004 Jan;26(1):49-60.

Decker DA, Pettinga JE, VanderVelde N, et al. Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. *Menopause*. 2003 Jul-Aug;10(4):277-85.

Suriano KA, McHale M, McLaren CE, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. *Obstet Gynecol*. 2001 Apr;97(4):555-60.

Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA*. 2000 Jan 26;283(4):485-91.

Jancin B. Adding progestin to estrogen multiplies breast cancer risk. *Family Practice News*. 2001 Mar 15.

Walling AD. Does HRT Increase the Risk of Breast Cancer? *Am Fam Physician*. 2002 Mar 1;65(5):947.

Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. *Med J Aust.* 2002 Oct 7;177(7):347-51.

O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. *J Natl Cancer Inst.* 2001 May 16;93(10):754-62.

Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. *N Engl J Med.* 1989 Aug 3;321(5):293-7.

Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. *JAMA.* 2006 Apr 12;295(14):1647-57.

James-Enger K. Cancer prevention breakthrough. *Redbook.* 2001 Mar;196(3):132.

Gizard F, Robillard R, Gervois P, et al. Progesterone inhibits human breast cancer cell growth through transcriptional upregulation of the cyclin-dependent kinase inhibitor p27Kip1 gene. *FEBS Lett.* 2005 Oct 24;579(25):5535-41.

Levgur M. Hormone therapy for women after breast cancer. *J of Reprod Med.* 2004 Jul;49(7):510-26.

Natrajan PK, Gambrell RD. Estrogen replacement therapy in patients with early breast cancer. *Am J Obstet Gynecol.* 2002 Aug;187(2):289-94.

Campagnoli C, Abba C, Amgroggio S, Peris C. Pregnancy, progesterone and progestins in relation to breast cancer risk. *J of Steroid Biochem & Molecular Biol.* 2005;97:441-450.

O'Meara ES, Rossing MA, Daling JR, et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. *J Natl Cancer Inst.* 2001 May 16;93(10):754-62.

Meurer LN, Lená S. Cancer recurrence and mortality in women using hormone replacement therapy: meta-analysis. *J Fam Pract.* 2002 Dec;51(12):1056-62.

Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. *Menopause.* 2004 Sep-Oct;11(5):531-5.

Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. *Climacteric.* 2002 Jun;5(2):151-5.

Decker DA, Pettinga JE, VanderVelde N, et al. Estrogen replacement therapy in breast cancer survivors: a matched-controlled series. *Menopause.* 2003 Jul-Aug;10(4):277-85.

Guidozzi F. Estrogen replacement therapy in breast cancer survivors. *Int J Gynaecol Obstet.* 1999 Jan;64(1):59-63.

Peters GN, Fodera T, Sabol J, et al. Estrogen replacement therapy after breast cancer: a 12-year follow-up. *Ann Surg Oncol.* 2001 Dec;8(10):828-32.

Vassilopoulou-Sellin R, Cohen DS, et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. *Cancer.* 2002 Nov 1;95(9):1817-26.

Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, et al. Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. *J Clin Oncol.* 1999 May;17(5):1482-7.

Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. *Med J Aust.* 2002 Oct 7;177(7):347-51.

Natrajan PK, Soumakis K, Gambrell RD Jr. Estrogen replacement therapy in women with previous breast cancer. *Am J Obstet Gynecol.* 1999 Aug;181(2):288-95.

Guidozzi F. Announcing the winner of the IJGO prize paper award for 1999. Estrogen replacement therapy in breast cancer survivors. *Int J Gynaecol Obstet.* 2000 May;69(2):101-2.

Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. *J Natl Cancer Inst.* 2008 Oct 1;100(19):1361-7.

Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. *Arch Intern Med.* 2006 May 8;166(9):1027-32.

Rock CL, Flatt SW, Laughlin GA, et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2008 Mar;17(3):614-20.

Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. *Obstet Gynecol.* 2006 Dec;108(6):1354-60.

Wood CE, Register TC, Lees CJ, et al. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. *Breast Cancer Res Treat.* 2007 Jan;101(2):125-34.

Foidart JM, Colin C, Denoo X, et al. Estradiol and progesterone regulate the proliferation of human breast epithelial cells. *Fertil Steril.* 1998 May;69(5):963-9.

Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. *Int J Cancer.* 2005 Apr 10;114(3):448-54.

de Lignieres B. Endometrial hyperplasia. Risks, recognition and the search for a safe hormone replacement regimen. *J Reprod Med.* 1999 Feb;44(2 Suppl):191-6.

Vashisht A, Wadsworth F, Carey A, et al. A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. *Gynecol Endocrinol*. 2005 Aug;21(2):101-5.

Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. *J Natl Cancer Inst*. 1995 Apr 5;87(7):517-23.

Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). *J Natl Cancer Inst*. 2005 May 18;97(10):755-65.

Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. *Int J Cancer*. 2004 Nov 1;112(2):312-8.

Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. *N Engl J Med*. 2009 Feb 5;360(6):573-87.

Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. *JAMA*. 2006 Apr 12;295(14):1647-57.

L'hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. *Maturitas*. 2008 Jul-Aug;60(3-4):185-201.

Kaunitz AM. HT and breast cancer: does the type of progestin matter? *OBG Management*. 2007 June;19(6):31-35.

Barbieri RL. More data on hormone therapy risks arrive to reshape practice. *OBG Management*. 2008 Aug;20(8).

Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. *J Natl Cancer Inst*. 2008 Apr 2;100(7):475-82.

Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat*. 2008 Jan;107(1):103-11.

de Lignieres B, de Vathaire F, Fournier S, et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. *Climacteric*. 2002;5:332-340.

Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). *J Natl Cancer Inst*. 2005 May 18;97(10):755-65.

Mauvais-Jarvis P, Kuttann F, Gompel A. Antiestrogen action of progesterone in breast tissue. *Breast Cancer Res Treat*. 1986;8(3):179-88.

Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignières B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. *Fertil Steril.* 1995 Apr;63(4):785-91.

Hughes S. Endocrinologist association encourages hrt in younger women. *Heartwire.* 2008 Jan 7.

Formby B, Wiley TS. Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. *Mol Cell Biochem.* 1999 Dec;202(1-2):53-61.

Moe BG, Vereide AB, Orbo A, Sager G. High concentrations of progesterone and mifepristone mutually reinforce cell cycle retardation and induction of apoptosis. *Anticancer Res.* 2009 Apr;29(4):1053-8.

Wang H, Zhou L, Gupta A, Vethanayagam RR, et al. Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. *Am J Physiol Endocrinol Metab.* 2006 May;290(5):E798-807.

Yu S, Lee M, Shin S, Park J. Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. *J Cell Biochem.* 2001;82(3):445-51.

Cleary MP, Grossmann ME. Minireview: Obesity and breast cancer: the estrogen connection. *Endocrinology.* 2009 Jun;150(6):2537-42.

Eisen A, Lubinski J, Gronwald J, et al. Hormone Therapy and the Risk of Breast Cancer in BRCA1 Mutation Carriers. *JNCI J Natl Cancer Inst.* 2008;100(19):1361- 1367.

Testosterone & Breast Cancer prevention

Radosh L. Drug treatments for polycystic ovary syndrome. *Am Fam Physician.* 2009 Apr 15;79(8):671-6.

Secreto G, Venturelli E, Meneghini E, et al. Testosterone and biological characteristics of breast cancers in postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2009 Nov;18(11):2942-8.

Schneider ME. Metformin regimen found to quell acne in polycystic ovary syndrome. *Skin & Allergy News.* 2007 October 1.

Somboonporn W, Davis SR, et al. Testosterone effects on the breast: implications for testosterone therapy for women. *Endocr Rev.* 2004 Jun;25(3):374-88.

- Panzer C, Guay A. Testosterone replacement therapy in naturally and surgically menopausal women. *J Sex Med.* 2009 Jan;6(1):8-18.
- Dimitrakakis C, Zhou J, Bondy CA. Androgens and mammary growth and neoplasia. *Fertil Steril.* 2002 Apr;77 Suppl 4:S26-33.
- Burgess HE, Shousha S. An immunohistochemical study of the long-term effects of androgen administration on female-to-male transsexual breast: a comparison with normal female breast and male breast showing gynaecomastia. *J Pathol.* 1993 May;170(1):37-43.
- Christgau S, Tankó LB, Cloos PA, et al. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). *Menopause.* 2004 Sep-Oct;11(5):508-18.
- Hofling M, Hirschberg AL, Skoog L, et al. Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. *Menopause.* 2007 Mar-Apr;14(2):183-90.
- Shufelt CL, Braunstein GD. Testosterone and the breast. *Menopause Int.* 2008 Sep;14(3):117-22.
- Davis SR, Hirschberg AL, Wagner LK, et al. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. *J Clin Endocrinol Metab.* 2009 Dec;94(12):4907-13.
- Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *J Natl Cancer Inst.* 2002 Apr 17;94(8):606-616.
- Lapointe J, Fournier A, Richard V, Labrie C. Androgens down-regulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. *Endocrinology.* 1999 Jan;140(1):416-21.
- Zhou J, Ng S, Adesanya-Famuyiwa O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. *FASEB J.* 2000 Sep;14(12):1725-30.
- Ortmann J, Prifti S, Bohlmann MK, et al. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. *Gynecol Endocrinol.* 2002 Apr;16(2):113-20.
- Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. *Menopause.* 2003 Jul-Aug;10(4):292-8.
- Gooren L. Testosterone supplementation: why and for whom? *Aging Male.* 2003 Sep;6(3):184-99.
- Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. *Cancer.* 1999 Sep 15;86(6):1013-8.

Bu SZ, Yin DL, Ren XH, et al. Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. *Cancer*. 1997 May 15;79(10):1944-50.

Sainz RM, Mayo JC, Tan DX, et al. Melatonin reduces prostate cancer cell growth leading to neuroendocrine differentiation via a receptor and PKA independent mechanism. *Prostate*. 2005 Apr 1;63(1):29-43.

Schernhammer ES, Berrino F, Krogh V, et al. Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. *J Natl Cancer Inst*. 2008 Jun 18;100(12):898-905.

Durna EM, Wren BG, Heller GZ, et al. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. *Med J Aust*. 2002 Oct 7;177(7):347-51.

DiSaia PJ, Brewster WR, Ziogas A, Anton-Culver H. Breast cancer survival and hormone replacement therapy: a cohort analysis. *Am J Clin Oncol*. 2000 Dec;23(6):541-545.

Gramling R, Eaton CB, Rothman KJ, et al. Hormone Replacement Therapy, Family History, and Breast Cancer Risk Among Postmenopausal Women. *Epidemiology*. 2009 Sep;20(5):752-756.

Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. *J Natl Cancer Inst*. 2008 Oct 1;100(19):1361-1367.

Chustecka Z. Exercise Reduces Risk for Premature Death From Cancer. *Medscape*. 2009 Aug 3. Accessed on February 20, 2013 from <http://www.medscape.com/viewarticle/706533>

Splete H. High BMI found to raise risk for most cancers. *OBGYN News*. 2008 Mar:19.
Worcester S. Young, healthy HRT users at low risk for CV event. *Family Practice News*. 2003 Jun 1. 33:11

Franklin BA, Shephard RJ. Avoiding Repeat Cardiac Events: The ABCDEs of Tertiary Prevention. *Phys Sportsmed*. 2000 Sep;28(9):31-58.

Recent rheumatology research results reported: American College of Rheumatology highlights current noteworthy studies. *J of Musculoskeletal Med*. 2004 Aug 1.

Estrogen/Progesterone Optimization

Toh S, Hernández-Díaz S, Logan R, et al. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. *Ann Intern Med.* 2010 Feb 16;152(4):211-7.

Grodstein F, Stampfer MJ. Estrogen for women at varying risk of coronary disease. *Maturitas.* 1998 Sep 20;30(1):19-26.

Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. *Circulation.* 1998 Sep 22;98(12):1158-63.

1. Kujala UM, Sarna S, Kaprio J, et al. Natural selection to sports, later physical activity habits, and coronary heart disease. *Br J Sports Med.* 2000 Dec;34(6):445-9.

2. Davison KK, Birch LL. Weight status, parent reaction, and self-concept in five-year-old girls. *Pediatrics.* 2001 Jan;107(1):46-53.

3. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. *Ann Intern Med.* 2000 Dec 19;133(12):933-41.

Johnson K. Oral contraceptives found protective against cardiovascular disease. *Family Practice News.* 2005 Aug 1.

Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. *JAMA.* 2001 Dec 12;286(22):2815-22.

Johnson K. ERT boosts cognitive function no matter the age. (unable to find full reference)

The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. *JAMA.* 1995 Jan 18;273(3):199-208.

Henderson VW, Benke KS, Green RC, et al. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. *J Neurol Neurosurg Psychiatry.* 2005 Jan;76(1):103-5.

Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. *Am J Med.* 2011 Mar;124(3):199-205.

Cooper AJ, White MI. Use of Pro-Gest cream in postmenopausal women. *The Lancet*. 1998 Sept 12;352:905-906.

Wren BG, McFarland K, Edwards L. Micronised transdermal progesterone and endometrial response. *Lancet*. 1999 Oct 23;354(9188):1447-8.

Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. *Am J Med*. 2011 Mar;124(3):199-205.

Progesterone Benefits

Toh S, Hernández-Díaz S, Logan R, et al. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. *Ann Intern Med*. 2010 Feb 16;152(4):211-7.

Pinkerton JV. Bioidentical hormones: What you (and your patient) need to know. *The J of Fam Practice*. 2009 Jan;21(1).

Tai PL. Avoid Common Pitfalls, Mistakes, and 87% Failures of Anti Aging Saliva Hormone Testing, The America Academy of Anti Aging Medicine 15th Annual International Congress on Anti aging Medicine & Regenerative Biomedical Technologies, Orlando, Florida, April 26, 2007.

Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. *Menopause*. 2004 May-Jun;11(3):356-67.

Ilyia ER, McLure D, Farhat MY. Long- Term Effects of Topical Progesterone Cream Application: A Case Study. *Inter J of Pharmaceutical Compounding*. June 1998.

Gavrilova N, Lindau ST. Salivary sex hormone measurement in a national, population-based study of older adults. *J Gerontol B Psychol Sci Soc Sci*. 2009 Nov;64:i94-105.

Arregger AL, Contreras LN, Tumilasci OR, et al. Salivary testosterone: a reliable approach to the diagnosis of male hypogonadism. *Clin Endocrinol*. 2007 Nov;67(5):656-62.

Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. *Menopause*. 2005 Mar;12(2):232-7.

Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. *Gynecol Endocrinol*. 2005 Aug;21(2):101-5.

MacFarland SA. Use of Pro-Gest cream in postmenopausal women. *The Lancet*. 1998 Sept 12;352:905.

Taylor-Robinson D, Ong G, Thomas BJ, Rose ML, Yacoub MH. Chlamydia pneumoniae in vascular tissues from heart-transplant donors. *Lancet*. 1998 Apr 25;351(9111):1255.

Wren BG, McFarland K, Edwards L. Micronised transdermal progesterone and endometrial response. *Lancet*. 1999 Oct 23;354(9188):1447-8.

Peck JD, Hulka BS, Poole C, et al. Steroid hormone levels during pregnancy and incidence of maternal breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2002 Apr;11(4):361-8.

Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. *Maturitas*. 2002 Jan 30;41(1):1-6.

de Lignières B. Effects of progestogens on the postmenopausal breast. *Climacteric*. 2002 Sep;5(3):229-35.

Formby B, Wiley TS. Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. *Mol Cell Biochem*. 1999 Dec;202(1-2):53-61.

McCrohon JA, Nakhla S, Jessup W, et al. Estrogen and progesterone reduce lipid accumulation in human monocyte-derived macrophages: a sex-specific effect. *Circulation*. 1999 Dec 7;100(23):2319-25.

Chang KJ, Lee TT, Linares-Cruz G, Fournier S, de Lignières B. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. *Fertil Steril*. 1995 Apr;63(4):785-91.

Blake EJ, Norris PM, Dorfman SF, et al. Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects. *Fertil Steril*. 2010 Sep;94(4):1296-301.

Schumacher M, Guennoun R, Ghoumari A, et al. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. *Endocr Rev*. 2007 Jun;28(4):387-439.

Darbinian JA, Ferrara AM, Van Den Eeden SK, et al. Glycemic status and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev*. 2008 Mar;17(3):628-35.

Rhoden EL, Morgentaler A. Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring. *N Engl J Med*. 2004;350(5):482-492.

Testosterone Benefits and Safety

Vermeulen A. Androgen replacement therapy in the aging male--a critical evaluation. *J Clin Endocrinol Metab.* 2001 Jun;86(6):2380-90.

Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. *J Clin Endocrinol Metab.* 1997 Nov;82(11):3793-6.

Fairbanks VF. What to include in the workup of an elevated hemoglobin concentration and hematocrit? (Hematology Q&A). *Consultant.* 2003 Jun 1.

Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. *JAMA.* 1989 Feb 24;261(8):1165-8.

Darbinian JA, Ferrara AM, Van Den Eeden SK, et al. Glycemic status and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev.* 2008 Mar;17(3):628-35.

Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. *Eur J Endocrinol.* 2006 Jun;154(6):899-906.

Gooren L. The role of testosterone in erectile function and dysfunction. *J of Men's Health & Gender.* 2006 Sept;3(3):292-298.

Al-Futaisi AM, Al-Zakwani IS, Almahrezi AM, Morris D. Subcutaneous administration of testosterone. A pilot study report. *Saudi Med J.* 2006 Dec;27(12):1843-6.

Tsujimura A, Matsumiya K, Takao T, et al. Treatment with human chorionic gonadotropin for PADAM: a preliminary report. *Aging Male.* 2005 Sep-Dec;8(3-4):175-9.

Shabsigh A, Kang Y, Shabsign R, et al. Clomiphene citrate effects on testosterone/estrogen ratio in male hypogonadism. *J Sex Med.* 2005 Sep;2(5):716-21.

Taylor F, Levine L. Clomiphene citrate and testosterone gel replacement therapy for male hypogonadism: efficacy and treatment cost. *J Sex Med.* 2010 Jan;7(1 Pt 1):269-76.

Potenza M, Shimshi M. Male hypogonadism: The unrecognized cardiovascular risk factor. *J Clin Lipidol.* 2008 Apr;2(2):71-8.

Hanafy HM. Testosterone therapy and obstructive sleep apnea: is there a real connection? *J Sex Med.* 2007 Sep;4(5):1241-6.

Gascón A, Belvis JJ, Berisa F, et al. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. *Geriatr Nephrol Urol.* 1999;9(2):67-72.

Santora LJ, Marin J, Vangrow J, et al. Coronary calcification in body builders using anabolic steroids. *Prev Cardiol.* 2006 Fall;9(4):198-201.

Low Testosterone in a Man With Prostate Cancer: What Are His Options? *Consultant Live.* 2006 Dec 31. Accessed on February 20, 2013 from <http://www.consultantlive.com/display/article/10162/38484>

Morgentaler A. A 66-Year-Old Man With Sexual Dysfunction. *JAMA.* 2004;291(24):2994-3003.

Hedrick RE, Ackerman RT, Koltun WD, et al. Transdermal estradiol gel 0.1% for the treatment of vasomotor symptoms in postmenopausal women. *Menopause.* 2009 Jan-Feb;16(1):132-40.

Update on HGH

Cummings DE, Merriam GR. Age-related changes in growth hormone secretion: should the somatopause be treated? *Semin Reprod Endocrinol.* 1999;17(4):311-25.

Simpson H, Savine R, Sonksen P, et al. Growth hormone replacement therapy for adults: Into the new millennium. *Growth Horm IGF Res.* 2002 Feb;12(1):1-33.

Jørgensen AP, Fougner KJ, Ueland T, et al. Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. *Growth Horm IGF Res.* 2011 Apr;21(2):69-75.

Thyroid vs. Cardiovascular disease & Osteoporosis

Feld S, Dickey RA. An Association Between Varying Degrees of Hypothyroidism and Hypercholesterolemia in Women: The Thyroid-Cholesterol Connection. *Prev Cardiol.* 2001 Autumn;4(4):179-182.

Ojamaa K. Thyroid Hormone Therapy of Cardiovascular Disease. *CVR & R.* 2002;23:20-26.

Garrison RL, Breeding PC. A metabolic basis for fibromyalgia and its related disorders: the possible role of resistance to thyroid hormone. *Med Hypotheses.* 2003 Aug;61(2):182-9.

Teitelbaum J. More Than Meets The Eye. *Healthy Aging.* 2(5):75-78. Accessed on February 20, 2013 from <http://healthy-aging.advanceweb.com/article/more-than-meets-the-eye-2.aspx>

Shomon M. The thyroid treatment/osteoporosis controversy: Does thyroid treatment contribute to loss of bone density? *Thyroid Info.* Accessed on February 20, 2013 from <http://www.thyroid-info.com/articles/osteoporosis.htm>

Thomasson WA. WCO: Thyroid Supplementation Does Not Increase Osteoporosis Risk. *Doctor's Guide.* 2000 Jun 17. Accessed on February 20, 2013 from <http://www.pslgroup.com/dg/1d62e2.htm>

De Rosa G, Testa A, Maussier ML, et al. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre. *Horm Metab Res.* 1995 Nov;27(11):503-7.

Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. *Ann Intern Med.* 1990 Aug 15;113(4):265-9.

Franklyn JA, Betteridge J, Daykin J, et al. Long-term thyroxine treatment and bone mineral density. *Lancet.* 1992 Jul 4;340(8810):9-13.

Schneider DL, Barrett-Connor EL, Morton DJ. Thyroid hormone use and bone mineral density in elderly men. *Arch Intern Med.* 1995 Oct 9;155(18):2005-7.

Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. *J Clin Endocrinol Metab.* 1996 Mar;81(3):1232-6.

Nuzzo V, Lupoli G, Esposito Del Puente A, et al. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy. *Gynecol Endocrinol*. 1998 Oct;12(5):333-7.

Fujiyama K, Kiriya T, Ito M, et al. Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women. *Thyroid*. 1995 Feb;5(1):13-7.

Sheppard MC, Holder R, Franklyn JA. Levothyroxine treatment and occurrence of fracture of the hip. *Arch Intern Med*. 2002 Feb 11;162(3):338-43.

Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. *Ann Intern Med*. 1999 May 4;130(9):750-8.

Shomon MJ, Cline W. Is Thyroid Medication Going to Give You Osteoporosis? Experts Evaluate the Risks. *About.com*. 2004 Mar 11. Accessed February 20, 2013 from <http://thyroid.about.com/cs/osteoporosis/a/osteoporosis.htm>

Van Den Eeden SK, Barzilay JI, Ettinger B, Minkoff J. Thyroid hormone use and the risk of hip fracture in women > or = 65 years: a case-control study. *J Womens Health*. 2003 Jan-Feb;12(1):27-31.

LRA by ELISA/ACT clinical update #16: Autoimmune thyroiditis:1-6.

DHEA Update

Pepping J. DHEA: dehydroepiandrosterone. *Am J Health Syst Pharm*. 2000 Nov 15;57(22):2048-50, 2053-4, 2056.

Hormones & Weight Loss

Chmouliovsky L, Habicht F, James RW, et al. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. *Maturitas*. 1999 Aug 16;32(3):147-53.

Mayes JS, Watson GH. Direct effects of sex steroid hormones on adipose tissues and obesity. *Obes Rev*. 2004 Nov;5(4):197-216.

OHSU researchers uncover cause, possible treatment for abdominal fat in postmenopausal women. 2005 Jun 6. Accessed on February 22, 2013 from http://www.eurekalert.org/pub_releases/2005-06/ohs-oru060605.php

Female Patient. 2001 April;26:18-24.

Goldman EL. 'Syndrome W' in Perimenopausal Women. Family Practice News. 1999

July 1.

Simkin-Silverman LR, Wing RR. Weight gain during menopause: Is it inevitable or

can it be prevented? Postgraduate Med. 2000 Sept 1. 108(3):47-55. Menopause matters. The Female Patient. 2000 Sept;25:61.

Heart Disease prevention

Stukel TA, Lucas FL, Wennberg DE. Long-term outcomes of regional variations in intensity of invasive vs medical management of Medicare Patients with acute myocardial infarction. JAMA. 2005 Mar 16;293(11):1329-37.

Chrysant SG, Ibrahim M. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol. J Clin Hypertens. 2006 Jul;8(7):493-9.

Despite Advances, Coronary Heart Disease Deaths Rise. Emergency Medicine News. 2001;23(8):42-43.

Dayspring TD. Coronary artery disease prevention in women. The Female Patient. 2001 Jan;26:47-53.

Sacco RL, Benson RT, Kargman DE, et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA. 2001 Jun 6;285(21):2729-35.

Brincat MP, Baron Y, Galea R. Estrogens and the skin. Climacteric. 2005;8:110-123.

Goldman EL. Est benefits skin thickness, elasticity.

Mayeaux EJ, Johnson C. Current concepts in postmenopausal hormone replacement therapy. J Fam Pract. 1996 Jul;43(1):69-75.

Schmidt JB, Binder M, Demschik G, Bieglmayer C, Reiner A. Treatment of Skin Aging with Topical Estrogens. Int J of Pharma Compounding. 1998 Jul/Aug.

Boschert S. Help Patients Assess Antiaging Product Claims. Family Practice News. 1999 July 1

Baumann LS. Cosmeceutical Critique: Soy and its isoflavones. Skin & Allergy News. 2001 Aug;17.

Schmidt JB, Binder M, Demschik G, et al. Treatment of skin aging with topical estrogens. *Int J Dermatol*. 1996 Sep;35(9):669-74.

Dunn LB, Damesyn M, Moore AA, et al. Does estrogen prevent skin aging? Results from the First National Health and Nutrition Examination Survey (NHANES I). *Arch Dermatol*. 1997 Mar;133(3):339-42.

Hargrove JT, Osteen KG. An alternative method of hormone replacement therapy using the natural sex steroids. *Infert Repro Med Clin N Am*. 1995;6:653-674.

Cardiology Management

HDL better predictor of ischemic stroke than LDL triglycerides. *Cardiology Review*. 2005 Mar. 22(3):529.

Clinical Insights in Diabetes. National Diabetes Education Initiative. Accessed on February 22, 2013. <http://www.ndei.org/Clinical-Insights-in-Diabetes.aspx>

Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. *Arch Intern Med*. 2000 Apr 24;160(8):1177-84.

Cost effectiveness of Statins. *Hospital Practice*. 2000 July 15. 24(7):33. Sadovsky R. Increasing low levels of high-density lipoprotein. *Am Fam Physician*.

2001 Jun 15;63(12):2435-2436.

Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. *Am J Cardiol*. 2000 Dec 21;86(12A):19L-22L.

Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. *Am J Cardiol*. 2000 Dec 21;86(12A):35L-40L.

Sprecher DL. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. *Am J Cardiol*. 2000 Dec 21;86(12A):46L-50L.

Jancin B. Testosterone replacement curbs inflammatory cytokines. *Clinical Psychiatry News*. 2004 May.

Kain D. First comprehensive paper on statins' adverse effects released. 2009 Jan 26. Accessed on February 22, 2012 from http://www.eurekalert.org/pub_releases/2009-01/uoc--fcp012609.php

Lu Z, Kou W, Du B, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. *Am J Cardiol*. 2008 Jun 15;101(12):1689-93.

Becker DJ, Gordon RY, Halbert SC, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. *Ann Intern Med*. 2009 Jun 16;150(12):830-9, W147-9.

Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. *Arch Intern Med*. 2010 Jun 28;170(12):1024-31.

Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. *J Altern Complement Med*. 2001 Apr;7(2):133-9.

Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! *Arch Intern Med*. 2010 Oct 25;170(19):1722-7.

Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. *J Manag Care Pharm*. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1.

Ling L, Zhao SP, Gao M, et al. Vitamin C preserves endothelial function in patients with coronary heart disease after a high-fat meal. *Clin Cardiol*. 2002 May;25(5):219-24.

Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. *Expert Rev Cardiovasc Ther*. 2008 Mar;6(3):391-409.

Heber D, Lembertas A, Lu QY, Bowerman S, Go VL. An analysis of nine proprietary Chinese red yeast rice dietary supplements: implications of variability in chemical profile and contents. *J Altern Complement Med*. 2001 Apr;7(2):133-9.

Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! *Arch Intern Med*. 2010 Oct 25;170(19):1722-7.

Yancy WS, Voleck JS, Westman EC. Nonfasting Triglycerides and Cardiovascular Risk. *JAMA*. 2007;298(17):2004-2008

Macready N. New pyramid reflects preventive role of nutrients: food and supplements for older adults. *Family Practice News*. 2003 Sept 1:29.

PCOS

Jancin B. Hyperinsulinemia, Not Ovaries, at Core of PCOS. *Family Practice News*. 2001 Jan 15;26.

Samraj G. How should I manage this young woman with menstrual abnormalities and hirsutism? *Family Practice Recertification*. 2001 Dec;23(14):608-610.

Hunter MH, Sterrett J. Polycystic ovary syndrome: It's not just infertility. *American Family Physician*. 2000 Sept 1;62(5):1079-1087.

Polycystic Ovary Syndrome. *Am Fam Physician*. 2009 Apr 15;79(8).

Richardson MR. Current perspectives in polycystic ovary syndrome. *Am Fam Physician*. 2003 Aug 15;68(4):697-704.

Hair loss

Lohr E. Alopecia nearly epidemic in black women; hairstyles blamed: tight braids, extensions. *Family Practice News*. 2004 Jun 1.

Bandaranayake I, Mirmirani P. Hair loss remedies--separating fact from fiction. *Cutis*. 2004 Feb;73(2):107-14.

Mounsey AL, Reed SW. Diagnosing and treating hair loss. *Am Fam Physician*. 2009 Aug 15;80(4):356-62.

Osteoporosis & Estrogen Metabolites

Weinerman SA, Miller EH. Foreword: The osteoporosis problem redefined. *J of Musculoskeletal Med.* 2007 Jun:S3.

Yates J, Barrett-Connor E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. *Obstet Gynecol.* 2004 Mar;103(3):440-446.

Miller KE. Osteoporosis prevention in postmenopausal women. *Am Fam Physician.* 2005 Sep 1;72(5):926-928.

Jancin B. Hormones studied to promote bone formation. *Family Practice News.* 2001 Nov 1.

Simon JA, Mack CJ. Preventing osteoporosis and improving compliance with HRT. *Contemporary OB/GYN for the Nurse Practitioner.* In: Bachmann GA. HRT putting the latest into practice. 2001:4-9.

Sutton R, Dian L, Guy P. Osteoporosis in men: An underrecognized and undertreated problem. *BCMJ.* 2011 Dec: 53(10):535-540.

Walsh N. Dietary Supplement Ipriflavone Stems Bone Loss. *Family Practice News.* 2001 Apr 15;31(8):32.

Daniell HW. Periodontitis in estrogen-deficient women. *Arch Intern Med.* 2002 Dec 9-23;162(22):2634-5.

Civitelli R, Pilgram TK, Dotson M, et al. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial. *Arch Intern Med.* 2002 Jun 24;162(12):1409-15.

Paganini-Hill A. The benefits of estrogen replacement therapy on oral health. The Leisure World cohort. *Arch Intern Med.* 1995 Nov 27;155(21):2325-9.

Villareal DT, Binder EF, Williams DB, et al. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. *JAMA.* 2001 Aug 15;286(7):815-20.

Vogel JJ. Selecting Bioidentical Hormone Therapy.

Gotherstrom G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. *J Clin Endocrinol Metab.* 2001 Oct;86(10):4657- 65.

Franco C, Brandberg J, Lonn L, et al. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: A 12-month placebo-controlled trial. *JCEM*. 2005;90: 1466-1474.

Birge SJ. Nonvertebral "osteoporotic" fractures: a brain disease or bone disease? *Menopause*. 2007 Jan-Feb;14(1):1-2.

Naessen T, Lindmark B, Lagerström C, et al. Early postmenopausal hormone therapy improves postural balance. *Menopause*. 2007 Jan-Feb;14(1):14-9.

Cesareo R, Napolitano C, Iozzino M. Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal. *Int J Womens Health*. 2010 Aug 9;2:1-6.

Osteoporosis: Protecting and strengthening bones naturally. *The Standard*. 2004;6(2):1-8.

Estrogen in Men

Zitzmann M, Erren M, Kamischke A, et al. Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. *J Clin Endocrinol Metab*. 2005 Dec;90(12):6603-8.

Zumpe D, Clancy AN, Michael RP. Progesterone decreases mating and estradiol uptake in preoptic areas of male monkeys. *Physiol Behav*. 2001 Nov-Dec;74(4- 5):603-12.

Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. *Eur J Cancer*. 2008 May;44(7):928- 36.

Bosland MC. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. *Ann N Y Acad Sci*. 2006 Nov;1089:168-76.

Carruba G. Estrogens and mechanisms of prostate cancer progression. *Ann N Y Acad Sci*. 2006 Nov;1089:201-17.

Estrogen plays critical role in regulating bone metabolism in men. *Reuters Medical News*. 2001 Jan 26.

Amin S, Zhang Y, Felson DT, et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. *Am J Med*. 2006 May;119(5):426-33.

Moon MA. Estradiol Prevents Bone Loss Due to Prostate Cancer Therapy. *Family Practice News*.

Estrogen plays critical role in regulating bone metabolism in men. Reuters Medical News. 2001 Jan 26.

Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, et al. Serum oestradiol and oestrogen-receptor gene polymorphism are associated with bone mineral density independently of serum testosterone in normal males. Clin Endocrinol. 1998 Dec;49(6):803-9.

Arnlov J, Pencina MJ, Amin S, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006 Aug 1;145(3):176-84.

Carani C, Rochira V, Faustini-Fustini M, et al. Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clin Endocrinol. 1999 Oct;51(4):517-24.

Cherrier MM, Matsumoto AM, Amory JK, et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology. 2005 Jan 25;64(2):290-6.

Gooren LJ, Toorians AW. Significance of oestrogens in male (patho)physiology. Ann Endocrinol. 2003 Apr;64(2):126-35.

Giri S, Thompson PD, Taxel P, et al. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men. Atherosclerosis. 1998 Apr;137(2):359-66.